Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.
Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients with PNENs.
Materials and methods: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013. Dihydropyrimidin-Dehydrogenase (DPD) and Thymidylat-Synthase (TS) expression was correlated with treatment response in 19 patients who had available tumor tissue and response data. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
To read results and conclusion, please login ...
Further abstracts you may be interested in